<unk>  (trade name Incruse Ellipta) is a long-acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It is also approved for this indication in combination with vilanterol (as<unk> /vilanterol) and also as a triple-therapy combination as fluticasone furoate/umeclidinium<unk> /vilanterol. It is on the World Health Organization's List of Essential Medicines.
Umeclidinium bromide
Aclidinium bromide
Tiratricol
Chloropicrin
Epiestriol
Plerixafor
Molsidomine
Roxadustat